Quintiles, the world’s largest life science services firm, is expanding its suite of services that it says will help drug companies bring products to market and speed up sales.

Called Allume, the package is described as a “go-to-market service.”

According to Quintiles, Allume “simplifies and organizes the complex and resource-intensive launch planning process; provides unique data-driven insights from 15 years of market entry experience across the globe; and taps Quintiles’ local market and therapeutic category expertise.”

Allume includes consulting services along with software plus support in clinical and commercial development.

“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, vice president of Consulting for Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets. Through Allume™ Quintiles provides the strategic thinking, local market knowledge, deep therapeutic insight and market access approaches to help our customers map and navigate a pathway to commercial success.”

[QUINTILES ARCHIVE: Check out a decade of Quintiles stories as reported in WRAL Tech Wire.]